Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ: SNY )

53.54 +0.52 (+0.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
34 35 Next >
4 Undervalued Biotech Stocks to Add to Your Buy List
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns. 
Via InvestorPlace
How To Attend Sanofi Q1 2022 Earnings Conference Call
Sanofi (NASDAQ:SNY) will host a conference call at 08:30 AM ET on April 28, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
As Evolving Pandemic Response, Officials Shift To Personal Choice On COVID-19 Boosters, Masks: WSJ
In the latest phase of the COVID-19 pandemic, federal and local officials are leaving it up to people to assess if they need booster shots, whether to wear a mask and how long to isolate after a... 
Via Benzinga
Sanofi's Rilzabrutinib Data In Autoimmune Blood Disorder Published In New England Journal of Medicine
Via Benzinga
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027
Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent... 
Via FinancialNewsMedia
Exposures COVID-19
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Friday Stocks Update
Royal Dutch Shell rose again on its earnings but is still at a p/e ratio of under 11x earnings. 
Via Talk Markets
What Is RSV, And Why Is Pfizer Paying Up To $525M For Treatment Candidates?
Pharma giant Pfizer, Inc. (NYSE: PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier. 
Via Benzinga
The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Did Truist Lower IGM Biosciences' Price Target?
Via Benzinga
Why Is IGM Biosciences (IGMS) Stock Up Today?
Here are the various catalysts investors in IGM Biosciences and IGMS stock are watching today as shares more than double. 
Via InvestorPlace
Stocks That Hit 52-Week Highs On Thursday
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
Europe Approves Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6-11 Years With Type 2 Inflammation
The  
Via Benzinga
Biden To Propose Change To Obamacare To Extend Subsidies For Families: WSJ
Via Benzinga
Sanofi To List Drug Ingredient Spin-Off EUROAPI On Euronext Paris in May
Sanofi SA (NASDAQ: SNY) plans to list its drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business. 
Via Benzinga
House Passes Bill To Cap Out-of-Pocket Insulin Costs To No More Than $35/Month
The House of Representatives voted to approve legislation that would limit cost-sharing for insulin under private health insurance and Medicare.  
Via Benzinga
EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine
Via Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Mid-Afternoon Market Update: Dow Surges 250 Points; NeoGenomics Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow jumping over 250 points on Tuesday. 
Via Benzinga
Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness
President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM Biosciences signed an exclusive worldwide... 
Via Benzinga
Mid-Day Market Update: Crude Oil Down 2.5%; IGM Biosciences Shares Jump
U.S. stocks traded higher midway through trading, with the Dow jumping over 250 points on Tuesday. 
Via Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 88.1% to $0.38 after declining 9% on Monday. McCormick (NASDAQ: IGMS) shares jumped 49.8% to $22.46. Sanofi SA (... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; McCormick Profit Beats Estimates
U.S. stocks opened on a strong note on Tuesday, with the Dow jumping around 350 points this morning. 
Via Benzinga
IGM Biosciences Shares Surge After Oncology/Immunology Pact With Sanofi
Sanofi SA (NASDAQ: SNY) and IGM Biosciences Inc (NASDAQ: IGMS) have signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against  
Via Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) rose 40.1% to $21.00 in pre-market trading following announcement of collaboration with Sanofi (NASDAQ: SNY). Guardforce AI Co.,... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Higher Ahead Of Earnings, Fed Speakers
Pre-open movers 
Via Benzinga
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
Via AB Newswire
Exposures Product Safety
Regeneron-Sanofi's Dupixent Significantly Improved Signs, Symptoms In Chronic Itchy Skin Disease
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) have presented  
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.